TN2009000045A1 - Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level - Google Patents

Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level

Info

Publication number: TN2009000045A1
Authority: TN; Tunisia
Prior art keywords: treatment; heterocyclic compounds; diseases related; compounds suitable; lipid level
Prior art date: 2006-08-15

Application number

TN2009000045A

Other languages

English (en)

Inventor

Jianmin Fu

Rajender Kamboj

Shifeng Liu

Natalia Pokrovskaia

Vandna Raina

Shaoyi Sun

Zaihui Zhang

Natalie Dales

Julia Fonarev

Vishnumurthy Kodumuru

Original Assignee

Novartis Ag

Xenon Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-15

Filing date

2009-02-13

Publication date

2010-08-19

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39864516&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000045(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2009-02-13 Application filed by Novartis Ag, Xenon Pharmaceuticals Inc filed Critical Novartis Ag

2010-08-19 Publication of TN2009000045A1 publication Critical patent/TN2009000045A1/fr

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Diabetes (AREA)
Hematology (AREA)
Virology (AREA)
Obesity (AREA)
Endocrinology (AREA)
Dermatology (AREA)
Oncology (AREA)
Heart & Thoracic Surgery (AREA)
Molecular Biology (AREA)
Cardiology (AREA)
Rheumatology (AREA)
Physical Education & Sports Medicine (AREA)
Communicable Diseases (AREA)
Neurology (AREA)
Immunology (AREA)
Pulmonology (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Epidemiology (AREA)
Child & Adolescent Psychology (AREA)
Vascular Medicine (AREA)
Ophthalmology & Optometry (AREA)

TN2009000045A 2006-08-15 2009-02-13 Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level TN2009000045A1 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82245906P	2006-08-15	2006-08-15
PCT/US2007/075802 WO2008127349A2 (fr)	2006-08-15	2007-08-13	Composés organiques

Publications (1)

Publication Number	Publication Date
TN2009000045A1 true TN2009000045A1 (en)	2010-08-19

Family

ID=39864516

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TN2009000045A TN2009000045A1 (en)	2006-08-15	2009-02-13	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level

Country Status (27)

Country	Link
US (2)	US8063084B2 (fr)
EP (1)	EP2054408B1 (fr)
JP (1)	JP4972690B2 (fr)
KR (4)	KR20140019873A (fr)
CN (1)	CN101535303B (fr)
AR (1)	AR062360A1 (fr)
AU (1)	AU2007351498B2 (fr)
BR (1)	BRPI0716407A2 (fr)
CA (1)	CA2660201C (fr)
CL (1)	CL2007002348A1 (fr)
CO (1)	CO6241156A2 (fr)
CR (1)	CR10566A (fr)
ES (1)	ES2597453T3 (fr)
GT (1)	GT200900027A (fr)
IL (1)	IL196562A0 (fr)
MA (1)	MA30655B1 (fr)
MX (1)	MX2009001634A (fr)
MY (1)	MY153263A (fr)
NO (1)	NO20091083L (fr)
NZ (2)	NZ574222A (fr)
PE (3)	PE20110371A1 (fr)
RU (1)	RU2009109147A (fr)
TN (1)	TN2009000045A1 (fr)
TW (1)	TWI404718B (fr)
UA (1)	UA96766C2 (fr)
WO (1)	WO2008127349A2 (fr)
ZA (1)	ZA200900263B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2008127349A2 (fr)	2006-08-15	2008-10-23	Novartis Ag	Composés organiques
CA2672776A1 (fr)	2006-12-20	2008-06-26	Novartis Ag	Composes organiques
WO2009032668A2 (fr)	2007-08-28	2009-03-12	Irm Llc	Composés et compositions en tant qu'inhibiteurs de kinase
AR070429A1 (es) *	2008-02-20	2010-04-07	Xenon Pharmaceuticals Inc	Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasa
AU2013200845B2 (en) *	2008-02-20	2015-01-29	Xenon Pharmaceuticals Inc.	Heterocyclic inhibitors of stearoyl-CoA desaturase
US8445505B2 (en)	2008-06-25	2013-05-21	Irm Llc	Pyrimidine derivatives as kinase inhibitors
UY31929A (es)	2008-06-25	2010-01-05	Irm Llc	Compuestos y composiciones como inhibidores de cinasa
US9168248B2 (en)	2009-02-17	2015-10-27	Merck Canada Inc.	Spiro compounds useful as inhibitors of stearoyl-coenzyme A delta-9 desaturase
EP2459568A4 (fr)	2009-07-28	2013-02-27	Merck Frosst Canada Ltd	Nouveaux composés spiro utiles en tant qu'inhibiteurs de la stéaroyl-coenzyme a delta-9 désaturase
SG178869A1 (en) *	2009-10-01	2012-04-27	Novartis Ag	Pyrazole derivatives which modulate stearoyl-coa desaturase
WO2013009678A2 (fr) *	2011-07-08	2013-01-17	Indiana University Research And Technology Corporation	Compositions et méthodes de traitement d'infection par un norovirus
KR20140084164A (ko)	2011-10-15	2014-07-04	제넨테크, 인크.	암의 치료를 위한 scd1 길항제
EP2822931B1 (fr)	2012-03-09	2017-05-03	Inception 2, Inc.	Composés de triazolone et leurs utilisations
US9181261B2 (en) *	2012-05-22	2015-11-10	Merck Sharp & Dohme Corp.	TrkA kinase inhibitors, compositions and methods thereof
EP2852387A2 (fr)	2012-05-22	2015-04-01	Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.	Inhibiteurs sélectifs de cellules indifférenciées
CA2894281C (fr)	2012-12-20	2021-04-20	Inception 2, Inc.	Composes de triazolone et leurs utilisations
WO2015035059A1 (fr)	2013-09-06	2015-03-12	Inception 2, Inc.	Composés de triazolone et leurs utilisations
EP3138840B1 (fr) *	2014-04-28	2020-09-23	Jiangsu Kanion Pharmaceutical Co., Ltd.	Dérivé de thiadiazolidine comme anti-entérovirus 71
US10208081B2 (en)	2014-11-26	2019-02-19	Enanta Pharmaceuticals, Inc.	Bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
RS62110B1 (sr)	2015-03-31	2021-08-31	Enanta Pharm Inc	Derivati žučnih kiselina kao agonisti fxr/tgr5 i postupci njihove upotrebe
WO2017189651A1 (fr)	2016-04-26	2017-11-02	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
WO2017189663A1 (fr)	2016-04-26	2017-11-02	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
US10080741B2 (en)	2016-04-26	2018-09-25	Enanta Pharmaceuticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use thereof
WO2017201152A1 (fr)	2016-05-18	2017-11-23	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs procédés d'utilisation
WO2017201155A1 (fr)	2016-05-18	2017-11-23	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole utilisés comme agonistes de fxr et leurs méthodes d'utilisation
WO2017201150A1 (fr)	2016-05-18	2017-11-23	Enanta Pharmaceuticals, Inc.	Analogues de l'isoxazole comme agonistes de fxr et leurs procédés d'utilisation
EP3523298A4 (fr) *	2016-10-04	2020-06-24	Enanta Pharmaceuticals, Inc.	Analogues de l'isoxazole en tant qu'agonistes de fxr et leurs procédés d'utilisation
EP3529245A4 (fr)	2016-10-24	2020-12-23	Yumanity Therapeutics, Inc.	Composés et utilisations de ces derniers
WO2018081285A1 (fr)	2016-10-26	2018-05-03	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole contenant de l'urée utilisés comme agonistes de fxr et leurs procédés d'utilisation
EP3566055B1 (fr)	2017-01-06	2025-03-12	Janssen Pharmaceutica NV	Inhibiteurs de la scd pour le traitement de troubles neurologiques
US11873298B2 (en)	2017-10-24	2024-01-16	Janssen Pharmaceutica Nv	Compounds and uses thereof
US10689391B2 (en)	2017-12-12	2020-06-23	Enanta Pharmaceuticals, Inc.	Isoxazole analogs as FXR agonists and methods of use thereof
US10829486B2 (en)	2018-02-14	2020-11-10	Enanta Pharmacueticals, Inc.	Isoxazole derivatives as FXR agonists and methods of use thereof
WO2019183587A1 (fr)	2018-03-23	2019-09-26	Yumanity Therapeutics, Inc.	Composés et leurs utilisations
KR20220007845A (ko)	2019-01-24	2022-01-19	유마니티 테라퓨틱스, 인크.	화합물 및 이의 용도
WO2020231917A1 (fr)	2019-05-13	2020-11-19	Enanta Pharmaceuticals, Inc.	Dérivés d'isoxazole utilisés en tant qu'agonistes de fxr et leurs procédés d'utilisation
CN111961034A (zh) *	2019-05-20	2020-11-20	浙江同源康医药股份有限公司	用作ret激酶抑制剂的化合物及其应用
EA202192047A1 (ru)	2019-11-13	2021-12-08	Юманити Терапьютикс, Инк.	Соединения и их применение
GB202012969D0 (en) *	2020-08-19	2020-09-30	Univ Of Oxford	Inhibitor compounds
CN115286616A (zh) *	2022-07-27	2022-11-04	北京师范大学	结合sigma-2受体的四氢异喹啉和异吲哚啉类化合物、其制备方法和应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NL293361A (fr)	1962-05-30
CH455806A (de) *	1963-08-30	1968-05-15	Ciba Geigy	Verfahren zur Herstellung neuer Imidazole
CH463517A (de) *	1964-04-24	1968-10-15	Ciba Geigy	Verfahren zur Herstellung neuer Diazacycloalkanverbindungen
US4058617A (en) *	1972-10-04	1977-11-15	Ciba-Geigy Corporation	Imidazoles and pharmaceutical composition
CH590266A5 (fr) *	1972-10-04	1977-07-29	Ciba Geigy Ag
IL44282A (en)	1974-02-25	1979-01-31	Ciba Geigy Ag	1-(1-alkyl-4(5)nitro-imidazol-2-yl)-2-oxo-tetrahydroimidazole derivatives, their manufacture and pharmaceutical compositions containing them
NZ184081A (en) *	1976-06-01	1980-10-08	Velsicol Chemical Corp	1-thiazol-2-yl-1 3-imidazolidn-2-ones
US4086240A (en) *	1976-06-01	1978-04-25	Velsicol Chemical Corporation	1-Thiazolyl-5-phenoxy and phenylthioalkanoyloxyimidazolidinones
US4116969A (en)	1976-06-01	1978-09-26	Velsicol Chemical Company	1-thiazolyl-5-hydroxyimidazolidinones
FI90869C (fi) *	1986-11-14	1994-04-11	Tanabe Seiyaku Co	Menetelmä lääkeaineena käyttökelpoisten imidatsolidinonijohdannaisten valmistamiseksi
US5164403A (en) *	1991-04-05	1992-11-17	G. D. Searle & Co.	N-arylheteroarylalkyl imidazol-2-one compounds for treatment of circulatory disorders
KR19990014856A (ko) *	1995-05-17	1999-02-25	미디암 디, 메코너헤이	살진균성 시클릭 아미드
DE19732928C2 (de)	1997-07-31	2000-05-18	Gruenenthal Gmbh	Verwendung substituierter Imidazolidin-2,4-dion-Verbindungen als Schmerzmittel
DE69821132T2 (de) *	1997-10-27	2004-10-21	Takeda Chemical Industries Ltd	1,3-thiazole als adenosine a3 rezeptor antagonisten zur behandlung von asthma, allergien und diabetes
US6962933B1 (en)	1999-08-06	2005-11-08	Takeda Pharmaceutical Company Limited	Method for inhibiting p38 MAP kinase or TNF-α production using a 1,3-thiazole
DE60142692D1 (de)	2000-02-24	2010-09-09	Xenon Genetics Inc	Stearoyl-coa-desaturase zur identifizierung von triglyceridreduktionstherapeutika
EP1268474A2 (fr)	2000-03-30	2003-01-02	Takeda Chemical Industries, Ltd.	Composes de 1,3-thiazole substitues, production et utilisation desdits composes
JP2002302488A (ja) *	2000-03-30	2002-10-18	Takeda Chem Ind Ltd	置換１，３−チアゾール化合物、その製造法および用途
WO2002051442A1 (fr)	2000-12-26	2002-07-04	Takeda Chemical Industries, Ltd.	Co-prescriptions
WO2002085838A1 (fr)	2001-04-24	2002-10-31	Massachusetts Institute Of Technology	Formation par catalyse de cuivre de liaisons carbone-heteroatome et carbone-carbone
CA2450400A1 (fr)	2001-06-11	2002-12-19	Takeda Chemical Industries, Ltd.	Compositions medicinales
US6706739B2 (en) *	2001-08-21	2004-03-16	National Health Research Institute	Imidazolidinone compounds
ATE548354T1 (de) *	2002-07-24	2012-03-15	Ptc Therapeutics Inc	Ureido-substituierte benzoesäureverbindungen und ihre verwendung für die nonsense-suppression und behandlung von erkrankungen
SE0301232D0 (sv) *	2003-04-25	2003-04-25	Astrazeneca Ab	Novel use
US20090192191A1 (en)	2004-01-09	2009-07-30	Braj Bhushan Lohray	Substituted hydroxamic acid derivatives as tnf inhibitors
EP1621539A1 (fr)	2004-07-27	2006-02-01	Aventis Pharma S.A.	Dérivées d'urée cyclique substitués par un heterocycle, leur prépration et leur utilisation pharmaceutique comee inhibiteurs de kinases
JP4958786B2 (ja) *	2004-09-20	2012-06-20	ゼノン・ファーマシューティカルズ・インコーポレイテッド	複素環誘導体および治療薬としてのそれらの使用
CL2007001597A1 (es) *	2006-06-05	2008-05-16	Novartis Ag Xenon Pharmaceutic	Compuestos derivados de 2-oxo-piridin-1(2h)-il-tiazol, imidazol o tiofen-carboxamida; composicion farmaceutica; y uso para el tratamiento de una enfermedad mediada por la estearoil-coa-desaturasa, tal como sindrome metabolico, hipertension y diabetes
WO2008127349A2 (fr) *	2006-08-15	2008-10-23	Novartis Ag	Composés organiques
MX2009002019A (es)	2006-08-24	2009-03-09	Novartis Ag	Derivados de 2-(pirazin-2-il)-tiazol y 2-(1h-pirazol-3-il)-tiazol asi como compuestos relacionados como inhibidores de la estearoil-coa-desaturasa (scd) para el tratamiento de trastornos metabolicos, cardiovasculares, y otros.
CN101516877B (zh) *	2006-09-22	2013-09-11	诺瓦提斯公司	杂环有机化合物
CA2672776A1 (fr) *	2006-12-20	2008-06-26	Novartis Ag	Composes organiques
AR070429A1 (es) *	2008-02-20	2010-04-07	Xenon Pharmaceuticals Inc	Derivados de 1,3 tiazol como inhibidores de estearoil - coa -desaturasa
EP2307379A2 (fr)	2008-06-27	2011-04-13	Novartis AG	Composés organiques

2007
- 2007-08-13 WO PCT/US2007/075802 patent/WO2008127349A2/fr active Application Filing
- 2007-08-13 KR KR1020147001838A patent/KR20140019873A/ko not_active Withdrawn
- 2007-08-13 US US12/377,499 patent/US8063084B2/en not_active Expired - Fee Related
- 2007-08-13 MX MX2009001634A patent/MX2009001634A/es active IP Right Grant
- 2007-08-13 UA UAA200900859A patent/UA96766C2/ru unknown
- 2007-08-13 NZ NZ574222A patent/NZ574222A/en not_active IP Right Cessation
- 2007-08-13 CA CA2660201A patent/CA2660201C/fr not_active Expired - Fee Related
- 2007-08-13 KR KR1020097005250A patent/KR20090040385A/ko not_active Ceased
- 2007-08-13 CL CL200702348A patent/CL2007002348A1/es unknown
- 2007-08-13 NZ NZ598548A patent/NZ598548A/xx not_active IP Right Cessation
- 2007-08-13 PE PE2011000441A patent/PE20110371A1/es not_active Application Discontinuation
- 2007-08-13 ES ES07873509.9T patent/ES2597453T3/es active Active
- 2007-08-13 PE PE2007001082A patent/PE20081316A1/es not_active Application Discontinuation
- 2007-08-13 KR KR1020127026540A patent/KR20130036080A/ko not_active Ceased
- 2007-08-13 EP EP07873509.9A patent/EP2054408B1/fr active Active
- 2007-08-13 AR ARP070103586A patent/AR062360A1/es unknown
- 2007-08-13 JP JP2009524754A patent/JP4972690B2/ja not_active Expired - Fee Related
- 2007-08-13 CN CN2007800303661A patent/CN101535303B/zh not_active Expired - Fee Related
- 2007-08-13 AU AU2007351498A patent/AU2007351498B2/en not_active Ceased
- 2007-08-13 TW TW096129875A patent/TWI404718B/zh not_active IP Right Cessation
- 2007-08-13 PE PE2011000443A patent/PE20110341A1/es not_active Application Discontinuation
- 2007-08-13 RU RU2009109147/04A patent/RU2009109147A/ru unknown
- 2007-08-13 KR KR1020117011700A patent/KR20110077006A/ko not_active Ceased
- 2007-08-13 MY MYPI20090434A patent/MY153263A/en unknown
- 2007-08-13 BR BRPI0716407-6A patent/BRPI0716407A2/pt not_active IP Right Cessation
2009
- 2009-01-13 ZA ZA2009/00263A patent/ZA200900263B/en unknown
- 2009-01-15 IL IL196562A patent/IL196562A0/en unknown
- 2009-01-16 CR CR10566A patent/CR10566A/es not_active Application Discontinuation
- 2009-02-06 GT GT200900027A patent/GT200900027A/es unknown
- 2009-02-13 TN TN2009000045A patent/TN2009000045A1/fr unknown
- 2009-02-13 CO CO09014467A patent/CO6241156A2/es active IP Right Grant
- 2009-02-20 MA MA31653A patent/MA30655B1/fr unknown
- 2009-03-11 NO NO20091083A patent/NO20091083L/no not_active Application Discontinuation
2011
- 2011-09-13 US US13/231,075 patent/US8293768B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
MX2009001634A (es)	2009-02-25
AU2007351498B2 (en)	2012-04-05
US20100233116A1 (en)	2010-09-16
EP2054408A2 (fr)	2009-05-06
US8063084B2 (en)	2011-11-22
ES2597453T3 (es)	2017-01-18
TWI404718B (zh)	2013-08-11
PE20081316A1 (es)	2008-10-16
PE20110341A1 (es)	2011-06-21
TW200815427A (en)	2008-04-01
CO6241156A2 (es)	2011-01-20
KR20130036080A (ko)	2013-04-09
NZ574222A (en)	2012-03-30
PE20110371A1 (es)	2011-06-24
KR20110077006A (ko)	2011-07-06
WO2008127349A2 (fr)	2008-10-23
UA96766C2 (ru)	2011-12-12
CN101535303A (zh)	2009-09-16
GT200900027A (es)	2010-06-01
CA2660201A1 (fr)	2008-10-23
AU2007351498A1 (en)	2008-10-23
MY153263A (en)	2015-01-29
IL196562A0 (en)	2009-11-18
NZ598548A (en)	2013-09-27
WO2008127349A3 (fr)	2009-02-12
CR10566A (es)	2009-03-11
BRPI0716407A2 (pt)	2014-05-20
JP2010501488A (ja)	2010-01-21
CN101535303B (zh)	2012-07-18
KR20090040385A (ko)	2009-04-23
US20120004164A1 (en)	2012-01-05
KR20140019873A (ko)	2014-02-17
MA30655B1 (fr)	2009-08-03
NO20091083L (no)	2009-04-28
ZA200900263B (en)	2011-11-30
JP4972690B2 (ja)	2012-07-11
EP2054408B1 (fr)	2016-07-13
AR062360A1 (es)	2008-11-05
US8293768B2 (en)	2012-10-23
CA2660201C (fr)	2016-05-03
CL2007002348A1 (es)	2008-08-08
RU2009109147A (ru)	2010-09-27

Publication	Publication Date	Title
TN2009000045A1 (en)	2010-08-19	Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid level
WO2007143597A3 (fr)	2008-04-10	Composés organiques
JO3014B1 (ar)	2016-09-05	مثبط متغاير الحلقات للإنزيم المحدد لدرجة التخليق الحيوي للأحماض الدهنية غير المشبعة
WO2009156484A3 (fr)	2010-05-14	Composés organiques
MX2009006728A (es)	2009-09-09	Heterociclos de 5 miembros 2-sustituidos como inhibidores de scd.
MX2009006706A (es)	2009-07-02	Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
MX2009006704A (es)	2009-06-30	Derivados de amina triciclicos como inhibidores de proteina de tirosina cinasa.
TN2010000203A1 (en)	2011-11-11	Beta-lactamase inhibitors
MX2009004059A (es)	2009-04-27	Triazoles biciclicos como moduladores de proteina cinasa.
TW200714590A (en)	2007-04-16	Heterocyclic inhibitors of MEK and methods of use thereof
MX2009003658A (es)	2009-04-22	Compuestos heterociclicos que contienen nitrogeno biciclico para utilizarse como inhibidores de desaturasa de estearoilo-coa.
EA200901308A1 (ru)	2010-04-30	Ингибиторы белка, активирующего 5-липоксигеназу (flap)
MX2009010894A (es)	2009-10-26	Derivados de 3-hidroquinazolin-4-ona para utilizarse como inhibidores de estearoil-coa-desaturasa.
PL1979355T3 (pl)	2011-04-29	Pochodne spiro imidazoli jako modulatory PPAR
EP2476679A3 (fr)	2012-10-31	Triazoles substitués utilisés comme inhibiteurs AXL
WO2007092751A3 (fr)	2007-12-27	Composés et procédés pour moduler fxr
MX2009006339A (es)	2009-08-21	Compuestos y composiciones como inhibidores de actividad de receptor 1 de cannabinoide.
MX2009007337A (es)	2009-07-15	Indazoles sustituidos con 5-piridinona.
JO3602B1 (ar)	2020-07-05	مركبات بنزيميدازول بصفتها منظمات لمستقبلات في ار 1
EA201000895A1 (ru)	2010-12-30	Композиции и способы для лечения лизосомных болезней
TW200630090A (en)	2006-09-01	Triazoles useful as inhibitors of protein kinases
TN2012000085A1 (en)	2013-09-19	Pyrazole derivatives which modulate stearoyl-coa desaturase
WO2007081808A3 (fr)	2008-04-03	Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
TW200806293A (en)	2008-02-01	Methods of treatment with CETP inhibitors
TN2010000378A1 (en)	2011-12-29	Heterocyclic inhibitors of stearoyl-coa desaturase